Form 4: Cardiff Oncology's Chief Medical Officer Granted Stock Options

Fairooz Kabbinavar, Chief Medical Officer of Cardiff Oncology, received stock options for 205,008 shares on March 7, 2024.

Summary

• On March 7, 2024, Fairooz Kabbinavar, the Chief Medical Officer of Cardiff Oncology, Inc. (CRDF), was granted stock options for 205,008 shares.
• The exercise price of these options is $3.51 per share.
• The options vest 25% on March 7, 2025, and the remaining shares vest in 36 equal monthly installments thereafter, contingent upon continued service.
• Following this transaction, Kabbinavar beneficially owns 630,008 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and indicates confidence in the company's future, but it's not a major event.

Positives

• The granting of stock options to the Chief Medical Officer aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The vesting schedule of the stock options suggests an expectation of continued service from the Chief Medical Officer for at least the next four years.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Cardiff Oncology.
• Companies such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation plans.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance and retention.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see this as a sign of stability and commitment to the leadership team.

Key Dates